Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 5/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | CDC25A | P30304 | 9/20 | 0.36 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14287362 | 1.00 | PLK1 (0.38) | PLK1TRPV1PARK7ITGB3ITGAV | |
| SCHEMBL5110112 | 1.00 | PLK1 (0.38) | PLK1TRPV1PARK7ITGB3ITGAV | |
| SCHEMBL5117261 | 0.99 | TRPV1 (0.38) | PLK1TRPV1PARK7ITGB3ITGAV | |
| SCHEMBL14287364 | 0.99 | TRPV1 (0.38) | PLK1TRPV1PARK7ITGB3ITGAV | |
| SCHEMBL5119124 | 0.99 | TRPV1 (0.38) | PLK1TRPV1PARK7ITGB3ITGAV | |
| SCHEMBL5124438 | 0.96 | PARK7 (0.39) | PLK1TRPV1PARK7ITGB3ITGAV | |
| SCHEMBL5124873 | 0.96 | PARK7 (0.39) | PLK1TRPV1PARK7ITGB3ITGAV | |
| SCHEMBL5124417 | 0.96 | PARK7 (0.39) | PLK1TRPV1PARK7ITGB3ITGAV | |
| SCHEMBL5125102 | 0.96 | PARK7 (0.39) | PLK1TRPV1PARK7ITGB3ITGAV | |
| SCHEMBL14287369 | 0.96 | PARK7 (0.39) | PLK1TRPV1PARK7ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | claimed |
| EP-1828124-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development (FR) | 2007-09-05 | — | — | EP | claimed |
| WO-2006063863-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-06-22 | — | — | WO | claimed |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | PLK1 2258/4885TRPV1 121/4885PARK7 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.